2022 - Research.com Best Scientist Award
His main research concerns Cancer research, Lung cancer, Pathology, Cancer and Molecular biology. The various areas that Adi F. Gazdar examines in his Cancer research study include Methylation, Epidermal growth factor receptor, Carcinogenesis, Tumor suppressor gene and Mutation. His research integrates issues of Carcinoma, Lung, Loss of heterozygosity and Adenocarcinoma in his study of Lung cancer.
His Pathology research is multidisciplinary, incorporating perspectives in Cell and Respiratory disease. His research on Molecular biology also deals with topics like
His primary scientific interests are in Cancer research, Lung cancer, Pathology, Cancer and Molecular biology. His studies in Cancer research integrate themes in fields like Carcinogenesis, Methylation, Gene, Tumor suppressor gene and DNA methylation. His biological study deals with issues like Adenocarcinoma, which deal with fields such as KRAS.
His Pathology study integrates concerns from other disciplines, such as Respiratory disease and Loss of heterozygosity. His Cancer study incorporates themes from Immunology and Bioinformatics. The Molecular biology study which covers Cell culture that intersects with In vitro.
Adi F. Gazdar focuses on Cancer research, Lung cancer, Cancer, Adenocarcinoma and Internal medicine. The study incorporates disciplines such as Cell, Methylation, DNA methylation, Bioinformatics and Oncogene in addition to Cancer research. Lung cancer is a primary field of his research addressed under Pathology.
He interconnects Cell culture and Immunology in the investigation of issues within Cancer. Adi F. Gazdar has researched Adenocarcinoma in several fields, including Epithelial–mesenchymal transition and Copy-number variation. His Molecular biology research integrates issues from Gene expression, Gene expression profiling and Cell growth.
The scientist’s investigation covers issues in Lung cancer, Cancer research, Adenocarcinoma, KRAS and Cancer. His Lung cancer research includes themes of Carcinoma and Lung. The concepts of his Cancer research study are interwoven with issues in Cell growth, NEUROD1, Oncogene, Molecular biology and Regulation of gene expression.
His Adenocarcinoma research is multidisciplinary, incorporating elements of Cell cycle and Bioinformatics. His KRAS research incorporates themes from Malignant transformation, Epithelial–mesenchymal transition, Growth factor receptor, Gene mutation and Computational biology. In his study, Nuclear protein, Signal transduction and Cell culture is inextricably linked to Mutation, which falls within the broad field of Cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Detection and Isolation of Type C Retrovirus Particles From Fresh and Cultured Lymphocytes of a Patient With Cutaneous T-cell Lymphoma
Bernard J. Poiesz;Francis W. Ruscetti;Adi F. Gazdar;Paul A. Bunn.
Proceedings of the National Academy of Sciences of the United States of America (1980)
Evaluation of a Tetrazolium-based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity Testing
James Carmichael;William G. DeGraff;Adi F. Gazdar;John D. Minna.
Cancer Research (1987)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson.
Journal of Thoracic Oncology (2011)
High frequency of mutations of the PIK3CA gene in human cancers
Yardena Samuels;Zhenghe Wang;Alberto Bardelli;Natalie Silliman.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve;Richard M. Neve;Koei Chin;Jane Fridlyand;Jennifer Yeh.
Cancer Cell (2006)
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
Hisayuki Shigematsu;Hisayuki Shigematsu;Li Lin;Takao Takahashi;Masaharu Nomura.
Journal of the National Cancer Institute (2005)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean;Cameron Brennan;Jin-Yuan Shih;Gregory Riely.
Proceedings of the National Academy of Sciences of the United States of America (2007)
Expression of Multidrug Resistance Gene in Human Cancers
Lori J. Goldstein;Hanan Galski;Antonio Fojo;Mark Willingham.
Journal of the National Cancer Institute (1989)
p53: a frequent target for genetic abnormalities in lung cancer
Takashi Takahashi;Marion M. Nau;Itsuo Chiba;Michael J. Birrer.
Lung cancer in never smokers — a different disease
Sophie Sun;Joan H. Schiller;Adi F. Gazdar.
Nature Reviews Cancer (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: